Toi M - Search Results

1

The discrepancy between immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine therapy.

Toi M, Nakamura T, Wada T, Yamamoto A, Toge T, Niimoto M, Hattori T. Toi M, et al. Jpn J Surg. 1989 Nov;19(6):768-72. doi: 10.1007/BF02471732. Jpn J Surg. 1989. PMID: 2514309

2

Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.

Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Osaki A, et al. Among authors: toi m. Am J Surg. 1992 Oct;164(4):323-6. doi: 10.1016/s0002-9610(05)80897-9. Am J Surg. 1992. PMID: 1357997

3

Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.

Toi M, Hattori T, Akagi M, Inokuchi K, Orita K, Sugimachi K, Dohi K, Nomura Y, Monden Y, Hamada Y, et al. Toi M, et al. Cancer. 1992 Nov 15;70(10):2475-83. doi: 10.1002/1097-0142(19921115)70:10<2475::aid-cncr2820701014>3.0.co;2-p. Cancer. 1992. PMID: 1423177 Clinical Trial.

4

[Prognostic significance of expression of c-ERBB-2 oncoprotein in breast cancer patients].

Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Osaki A, et al. Among authors: toi m. Gan To Kagaku Ryoho. 1991 Jun;18(7):1181-5. Gan To Kagaku Ryoho. 1991. PMID: 1675844 Japanese.

5

[5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer].

Yoshinaka K, Yagi M, Ohtagaki S, Toi M, Toge T. Yoshinaka K, et al. Among authors: toi m. Gan To Kagaku Ryoho. 1991 Jan;18(1):115-8. Gan To Kagaku Ryoho. 1991. PMID: 1824814 Japanese.

6

Epidermal growth factor receptor expression as a prognostic indicator in breast cancer.

Toi M, Osaki A, Yamada H, Toge T. Toi M, et al. Eur J Cancer. 1991;27(8):977-80. doi: 10.1016/0277-5379(91)90262-c. Eur J Cancer. 1991. PMID: 1832907

7

Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer.

Mukaida H, Toi M, Hirai T, Yamashita Y, Toge T. Mukaida H, et al. Among authors: toi m. Cancer. 1991 Jul 1;68(1):142-8. doi: 10.1002/1097-0142(19910701)68:1<142::aid-cncr2820680126>3.0.co;2-x. Cancer. 1991. PMID: 2049734

8

Prospective randomized controlled study on bestatin in resectable gastric cancer--third report.

Niimoto M, Saeki T, Toi M, Nishiyama M, Hirai T, Yanagawa E, Hattori T. Niimoto M, et al. Among authors: toi m. Jpn J Surg. 1990 Mar;20(2):186-91. doi: 10.1007/BF02470767. Jpn J Surg. 1990. PMID: 2111415 Clinical Trial.

9

Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice.

Toi M, Mukaida H, Wada T, Hirabayashi N, Toge T, Hori T, Umezawa K. Toi M, et al. Eur J Cancer. 1990;26(6):722-4. doi: 10.1016/0277-5379(90)90126-e. Eur J Cancer. 1990. PMID: 2144161

10

Growth fractions of breast cancer in relation to epidermal growth factor receptor and estrogen receptor.

Toi M, Wada T, Yamada H, Ohsaki A, Yamamoto A, Nakamura T, Niimoto M, Hattori T. Toi M, et al. Jpn J Surg. 1990 May;20(3):327-30. doi: 10.1007/BF02470668. Jpn J Surg. 1990. PMID: 2162976

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

786 results

Search Page

Filters